Numab Therapeutics AG is an expanding, Swiss biotech company based in Horgen, canton of Zürich. The company is focused on the discovery and development of innovative, antibody fragment-based therapeutics with a focus on inflammation and immuno-oncology. With our breakthrough antibody-discovery and multi-specifics engineering platform, we engage in proprietary projects as well as collaborative research on behalf of partners in the pharmaceutical industry.